287119-83-9

Usage

Uses

Used in Organic Synthesis:
2-(2-Methyl-5-nitrophenyl)aceticacid is used as a versatile intermediate in organic synthesis for the preparation of a wide range of chemical compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of various organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(2-Methyl-5-nitrophenyl)aceticacid is employed as a key intermediate in the development of new drugs. Its chemical properties and reactivity allow for the creation of novel drug candidates with potential therapeutic applications.
Used in Drug and Agrochemical Development:
The presence of a nitro group in 2-(2-Methyl-5-nitrophenyl)aceticacid makes it a useful component in the synthesis of drugs and agrochemicals. Its reactivity and functional groups can be exploited to create new molecules with desired biological activities.
Used in Anti-inflammatory and Analgesic Applications:
2-(2-Methyl-5-nitrophenyl)aceticacid has been studied for its potential anti-inflammatory and analgesic properties. It is used as a starting material in the development of new pharmaceuticals aimed at treating inflammation and pain.
Used in Research and Development:
In the research industry, 2-(2-Methyl-5-nitrophenyl)aceticacid is utilized as a valuable chemical for the exploration of new chemical reactions and the synthesis of novel compounds. Its unique properties and reactivity make it an essential tool in the advancement of scientific knowledge and the discovery of new chemical entities.

InChI:InChI=1/C9H9NO4/c1-6-2-3-8(10(13)14)4-7(6)5-9(11)12/h2-4H,5H2,1H3,(H,11,12)

Upstream product

• 644-36-0 o-methylphenylacetic acid 
• 1975-52-6 5-nitro-o-toluic acid 
• 22474-47-1 (2-methyl-5-nitro-7-phenyl)methanol 
• 409082-10-6 (2-methyl-5-nitrophenyl)-methyl methylsulfonate 
• 409082-11-7 2-(2-methyl-5-nitrophenyl)acetonitrile 

Downstream Products

• 393837-02-0 2-(2-methanesulfonyloxyethyl)-1-methyl-4-nitrobenzene 
• 393837-10-0 7-chloro-3-{1-[2-(2-methyl-5-nitrophenyl)-1-oxoethyl]-piperidin-4-yl}-1H-indole 

Relevant academic research and scientific papers

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases. (formula Ia)

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

4-Saturated cyclosubstituted aniline protein kinase inhibitor

The invention discloses a compound being able to adjust the activity of protein kinase and used for treating or preventing protein kinase related diseases, concretely relates to a 4-saturated cyclosubstituted aniline protein kinase inhibitor belonging to a compound for adjusting the activity of anaplastic lymphoma kinase (ALK), and provides a preparation method of the compound and a pharmaceutical use of the compound in treatment or prevention of ALK related diseases.

IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR , PDGFR , CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF , SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2 , BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF beta , SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2 beta kinases.

Indole derivatives useful for the treatment of CNS disorders

The present invention relates to substituted indole derivatives of formula I wherein R1 is hydrogen or optionally substituted C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl or C3-8-cycloalkyl-C1-6-alkyl, or R1 is optionally substituted aryl, aryl-C1-6-alkyl, heteroaryl, heteroaryl-C1-6-alkyl or R1 is —NR′R″ wherein R′ and R″ are independently selected from hydrogen and optionally substituted C1-6-alkyl, aryl, aryl-C1-6-alkyl, heteroaryl and heteroaryl-C1-6-alkyl, or R1 is a saturated or partially saturated 5- to 6-membered ring containing one, two or three hetero atoms selected from O or S, and a group N—R9 wherein R9 is hydrogen or optionally substituted C1-6-alkyl; R2 is C1-6-alkyl W, n, X, R3-R8 are as defined in the description. The compounds of the invention are potent dopamine D4 ligands.

Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compound